Table 3.
Subject | t1/2 (days) | CL (ml h−1) | Vss (l) | AUC (0,∞) (µm h) | Absolute bioavailability (%) |
---|---|---|---|---|---|
Single dose | |||||
1 | 12.4 | 36.6 | 14.7 | 0.648 | 32.2 |
2 | 17.3 | 26.8 | 14.4 | 0.883 | 30.6 |
3 | 9.88 | 59.5 | 19.6 | 0.399 | 33.2 |
4 | 10.3 | 53.3 | 16.7 | 0.446 | 36.9 |
5 | 8.79 | 52.4 | 16.6 | 0.453 | 23.4 |
6 | 19.7 | 31.8 | 16.6 | 0.748 | 34.3 |
Mean | 13.0 | 43.4 | 16.4 | 0.596 | 31.8 |
CV% | 34.0 | 30.9 | 11.3 | 32.7 | 14.5 |
Multiple dose | |||||
13 | 7.42 | 106 | 32.6 | 0.223 | 10.90 |
14 | 15.30 | 61.0 | 29.9 | 0.389 | 5.28 |
15 | 10.80 | 78.2 | 29.6 | 0.304 | 8.89 |
16 | 5.67 | 71.8 | 17.4 | 0.330 | 7.40 |
17 | 9.38 | 89.1 | 29.4 | 0.266 | 7.85 |
18 | 13.50 | 64.6 | 22.0 | 0.368 | 3.82 |
Mean | 10.30 | 78.5 | 26.8 | 0.313 | 7.36 |
CV% | 35.1 | 21.4 | 21.7 | 20.0 | 34.4 |
t1/2, terminal phase half-life; CL, total plasma clearance; Vss, volume of distribution; AUC (0,∞), area under the plasma concentration–time curve from time 0 to infinity.